Item type |
itemtype_ver1(1) |
公開日 |
2023-07-27 |
タイトル |
|
|
タイトル |
Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer |
|
言語 |
en |
著者 |
Nakajima, Hiroki
Yamaguchi, Junpei
Takami, Hideki
Hayashi, Masamichi
Kodera, Yasuhiro
Nishida, Yoshihiro
Watanabe, Nobuyuki
Onoe, Shunsuke
Mizuno, Takashi
Yokoyama, Yukihiro
Ebata, Tomoki
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利 |
|
|
言語 |
en |
|
権利情報 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s10147-023-02321-1 |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Sarcopenia |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Psoas muscles |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Neoadjuvant chemotherapy |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Pancreatectomy |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Prognosis |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Neoadjuvant chemotherapy is a common therapeutic procedure for patients with pancreatic cancer. This study aimed to investigate the association between the total psoas area (TPA) and prognosis in patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. Study design: This retrospective study included patients who underwent neoadjuvant chemotherapy for pancreatic cancer. TPA was measured at the level of the L3 vertebra using computed tomography. The patients were divided into low-TPA and normal-TPA groups. These dichotomizations were separately performed in patients with resectable and those with borderline resectable pancreatic cancer. Results: In total, 44 patients had resectable pancreatic cancer and 71 patients had borderline resectable pancreatic cancer. Overall survival among patients with resectable pancreatic cancer did not differ between the normal- and low-TPA groups (median, 19.8 vs. 21.8 months, p = 0.447), whereas among patients with borderline resectable pancreatic cancer, the low-TPA group had shorter overall survival than the normal-TPA group (median, 21.8 vs. 32.9 months, p = 0.006). Among patients with borderline resectable pancreatic cancer, the low-TPA group was predictive of poor overall survival (adjusted hazard ratio, 2.57, p = 0.037). Conclusion: Low TPA is a risk factor of poor survival in patients undergoing neoadjuvant chemotherapy for borderline resectable pancreatic cancer. TPA evaluation could potentially suggest the treatment strategy in this disease. |
|
言語 |
en |
出版者 |
|
|
出版者 |
Springer |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s10147-023-02321-1 |
収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1341-9625 |
書誌情報 |
en : International Journal of Clinical Oncology
巻 28,
号 5,
p. 688-697,
発行日 2023-05
|
ファイル公開日 |
|
|
日付 |
2024-05-01 |
|
日付タイプ |
Available |